Eng Biocat

Implementing an Enzyme Engineering Technology Platform for the provision of tailor-made enzymes
for biocatalytic synthesis
Acronym: Eng Biocat
 
Project coordinator
- Dr. Marc Struhalla - c-LEcta GmbH, Leipzig - Germany

Project leaders
- Dr. Oliver May - DSM Pharmaceutical Products, Geleen - The Netherlands
- Mr. Russell Golson - BioSilta Oy, Oulu - Finland
- Dr. Monika Bollok - Bioingenium s.I., Barcelona - Spain
- Prof. John, M. Woodley - Technical University of Denmark, Lyngby - Denmark
- Prof. Dr. Gerold Barth - Institute of Microbiology, Technische Universitaet Dresden - Germany
- Prof. Dr. Peter Neubauer - University of Oulu - Finland
- Prof. Josep López-Santín - Universitat Autònoma de Barcelona. Escola Tècnica Superior d’Enginyeria, Bellaterra - Spain
- Prof. Dr. Hans-Jörg Hofmann & Dr. Robert Günther - Institute of Biochemistry/University Leipzig - Germany

Abstract
According to a market study of Mc Kinsey nowadays approximately 5% of all chemical products corresponding to more then 50 billion € sales are already produced by biotechnological processes and they are growing with 10-20% per year. No matter whether isolated enzymes, whole-cell biotransformations or fermentation processes are used for the production of bio-chemicals, these entire innovative biotechnological processes are based on technologies which need to provide defined enzymatic activities. Nowadays mainly naturally occurring enzymes are used to setup new bio-based synthesis routes whereas artificially optimized enzymes obtained by enzyme engineering technologies are not playing a very important role. This is mainly due to the cost-intensive and timeconsuming efforts which are connected to the established technologies in this field. Within this joint project it is intended to build up an innovative technology platform based on new proprietary methods decreasing costs and increasing speed of enzyme engineering projects. This should allow making enzyme engineering technologies to become a much more important tool for the development of biocatalytic processes and to supply a powerful approach to sustainably improve the competitiveness of the European chemical industry. This proof-of-concept will be established on two enzyme classes of high industrial relevance capable of realizing direct chiral synthesis: Lyases and Transaminases. By broadening the substrate spectrum of these enzymes towards new molecules a number of new chemical products will become efficiently available. The joint project will focus on innovations along all parts of the enzymatic value chain. Enzyme screening and production processes, immobilization techniques and biocatalytic processes themselves will also be addressed. All activities are focused on increasing the efficiency, decreasing the development times and lowering the costs of the final process.

Bijlages: